1. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death.Circulation . 2012;125(4):620-637. doi:10.1161/CIRCULATIONAHA.111.023838
2. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med . 1980;303(6):322-324. doi:10.1056/NEJM198008073030607
3. Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices.Heart Br Card Soc . 2015;101(22):1800-1806. doi:10.1136/heartjnl-2015-307634
4. Gold MR, Higgins S, Klein R, et al. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: primary results from the Low Energy Safety Study (LESS). Circulation . 2002;105(17):2043-2048. doi:10.1161/01.cir.0000015508.59749.f5
5. Neuzner J, Pitschner HF, Huth C, Schlepper M. Effect of biphasic waveform pulse on endocardial defibrillation efficacy in humans.Pacing Clin Electrophysiol PACE . 1994;17(2):207-212. doi:10.1111/j.1540-8159.1994.tb01373.x
6. Brignole M, Occhetta E, Bongiorni MG, et al. Clinical evaluation of defibrillation testing in an unselected population of 2,120 consecutive patients undergoing first implantable cardioverter-defibrillator implant. J Am Coll Cardiol . 2012;60(11):981-987. doi:10.1016/j.jacc.2012.05.014
7. Borne RT, Randolph T, Wang Y, et al. Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice.JAMA Netw Open . 2019;2(10):e1913553. doi:10.1001/jamanetworkopen.2019.13553
8. Olsovsky MR, Shorofsky SR, Gold MR. Effect of shock polarity on biphasic defibrillation thresholds using an active pectoral lead system.J Cardiovasc Electrophysiol . 1998;9(4):350-354. doi:10.1111/j.1540-8167.1998.tb00923.x
9. Denman RA, Umesan C, Martin PT, et al. Benefit of millisecond waveform durations for patients with high defibrillation thresholds.Heart Rhythm . 2006;3(5):536-541. doi:10.1016/j.hrthm.2006.01.027
10. Dopp AL, Miller JM, Tisdale JE. Effect of drugs on defibrillation capacity. Drugs . 2008;68(5):607-630. doi:10.2165/00003495-200868050-00004
11. Bollmann A, Husser D, Cannom DS. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators. Am J Cardiovasc Drugs Drugs Devices Interv . 2005;5(6):371-378. doi:10.2165/00129784-200505060-00004
12. Kroll MW, Schwab JO. Achieving low defibrillation thresholds at implant: pharmacological influences, RV coil polarity and position, SVC coil usage and positioning, pulse width settings, and the azygous vein.Fundam Clin Pharmacol . 2010;24(5):561-573. doi:10.1111/j.1472-8206.2010.00848.x
13. Gold MR, Olsovsky MR, Pelini MA, Peters RW, Shorofsky SR. Comparison of single- and dual-coil active pectoral defibrillation lead systems.J Am Coll Cardiol . 1998;31(6):1391-1394. doi:10.1016/s0735-1097(98)00103-x
14. Faheem O, Padala A, Kluger J, Zweibel S, Clyne CA. Coronary sinus shocking lead as salvage in patients with advanced CHF and high defibrillation thresholds. Pacing Clin Electrophysiol PACE . 2010;33(8):967-972. doi:10.1111/j.1540-8159.2010.02726.x
15. Kühlkamp V, Dörnberger V, Mewis C, Seipel L. Comparison of the efficacy of a subcutaneous array electrode with a subcutaneous patch electrode, a prospective randomized study. Int J Cardiol . 2001;78(3):247-256. doi:10.1016/s0167-5273(01)00381-3